Obesity Phenotype-targeted Treatment Choice Nearly Doubled Weight Loss in Clinical Trials: Investigator Interview
Obesity physician-scientist Andres Acosta, MD, PhD, reviews findings from recent studies he led that suggest true potential for phenotype-focused weight loss intervention.
US Mental Health Crisis Meets Limited Treatment Capacity: APA Survey Findings
While 60% of US psychologists have no openings for new patients, demand for treatment continues to rise, especially among adolescents and health care workers.
Bariatric Surgery Halves Adverse CVD Events in Patients with NAFLD, Severe Obesity
Bariatric surgery reduced by half the risk of CV events including myocardial infarction, heart failure, and stroke compared to nonsurgical care.
How to Build an Obesity Phenotype Step-by-Step, with Andres Acosta, MD, PhD
Obesity phenotyping uses a battery of validated tests and procedures to determine the root cause of a patient's disease and then match treatment accordingly.
Investigational Fentanyl Vaccine Could Block the Opioid from the Brain
A vaccine against fentanyl could stop the intense euphoria the drug creates and also block dangerous physiologic responses like respiratory depression, a new study suggests.
Obesity Phenotypes Explain What Drives the Disease and How to Target Intervention: Expert Interview
Mayo Clinic's Andres Acosta, MD, PhD, details the 4 biologic obesity phenotypes his team has identified and how their use can change weight loss outcomes.
Dupilumab Pooled Phase 3 Trial Data Broadly Support FDA Approval for EoE
Pooled phase 3 data from LIBERTY-EoE-TREET presented at ACAAI 2022 reinforce May 2022 FDA approval of dupilumab for eosinophilic esophagitis.
Andres Acosta, MD, Discusses the Challenge of Heterogeneity in Response to Obesity Treatment
Acosta, a pioneer in the phenotyping of obesity, says one-third of patients don't respond to treatment and he knows why.
Baxdrostat in Phase 2 Clinical Trial Proves Effective, Safe in Treatment-resistant Hypertension
Baxdrostat shows potential to represent the first new class of antihypertensive agents approved since 2017.
Fully Remote Intervention for Hypertension, Lipids Proves Feasible, Successful in Large, Diverse Health Care Network
The Mass General Brigham clinical intervention and study included 10 000 participants and resulted in significant reductions in SBP/DBP and LDL-C.
AACE President Discusses New Guideline Recommendations for Cardiorenal Protective Therapy in T2D
Use of GLP-1 mimetics and SGLT-2 inhibitors for cardiorenal protection in T2D patients is backed by robust clinical trial evidence, says AACE President Sethu Reddy, MD.
5 Cities Benefitting Most & Least from New Medical Debt Credit Reporting Changes
Equifax, Experian, and TransUnion announced 3 major changes to medical debt reporting, expected to remove ~70% of medical collection debt tradelines from consumer credit reports.
Management of Type 2 Diabetes Complications, Comorbidities Focus of AACE 2022 Guideline Update
AACE president Dr Sethu Reddy highlights evidence-based updates, including selection of diabetes medication based on comorbidities and new agents to treat DKD and elevated lipids.
Sotagliflozin Cuts Risk by >50% for Heart Failure Readmission, CV Death in Phase 3 SOLOIST-WHF Trial
In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.
Lifestyle Interventions Based on Obesity Phenotypes Significantly More Effective vs Standard Methods, Study Shows
The novel approach to targeted obesity treatment could improve weight loss outcomes, suggest findings from ObesityWeek® 2022.
Moderate-to-heavy Alcohol Consumption in Young Adulthood May Lead to Early Stroke, Warn New Study Findings
Study authors saw a positive dose-response relationship driven by hemorrhagic stroke in young adults who were moderate-to-heavy drinkers in their 20s and 30s.
Remote Electrical Neuromodulation Device Effective for Migraine Prevention in Pivotal Trial
The Nerivio REM device demonstrated a statistically significant reduction in migraine days/month vs a placebo device in both chronic and episodic migraine.
Empagliflozin Reduced Risk of Renal Disease Progression, CV Death Across CKD Spectrum in EMPA-KIDNEY
Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.
AACE President Sethu Reddy, MD, Highlights Updated 2022 Diabetes Guidelines for Primary Care
Reddy talks about the value of A1c vs results of an OGTT for T2D diagnosis, about glycemic targets and patient safety, hyperglycemia during pregnancy, and more in our interview.
Apixaban May be the Safer DOAC in Afib, Suggests First Large Comparative Analysis
Apixaban was associated with up to a 28% lower risk of GI bleeding vs the 3 other direct oral anticoagulants in the first large-scale comparative analysis.
7 RSV Myths and Facts: Prepare for the New Wave of Misinformation
RSV is back for the 2022-23 respiratory virus season and is unfamiliar to many. Click through this quick collection of myths already in circulation to prepare.
Semaglutide 2.4 mg (Wegovy) Yields "Amazing" Weight Loss in Adolescents, Similar to Adult Response
Semaglutide 2.4 mg (Wegovy) weight loss benefits in adolescents mirror those seen in adults, according to phase 3a trial findings presented at ObesityWeek® 2022.
Practice-related Factors in Primary Care May Limit Weight Management Services Offered
ObesityWeek® 2022. Primary care clinicians report providing on average just 70% of a wide range of clinical weight management services, according to a new survey.
RSV Older Adult Vaccine Candidate from GSK Wins FDA Priority Review, PDUFA Date Set
The FDA accepted the GSK BLA and granted priority review to what could be the first vaccine approved against RSV in adults aged ≥60 years, according to the company.
Maternal RSV Vaccine Prevents Infection in Infants, Pfizer Announces
Topline phase 3 trial data showed 81.8% efficacy for the maternal vaccine against severe RSV-related illness in infants from birth through first 90 days of life.
Investigational Glucagon Receptor/GLP-1 Receptor Dual Agonist Bests Semaglutide for Weight Loss in T2D Patients
ObesityWeek® 2022. Coagonism of the glucagon and GLP-1 receptors appears to result in greater weight loss than GLP-1 receptor agonism alone, study suggests.
Low Uptake of Antiobesity Medications Explored in Patient Perception Survey
ObesityWeek® 2022. Low awareness of antiobesity medications and concerns about cost, side effects revealed as barriers to wider uptake in a new study.
Black Patients with Afib Significantly Less Likely to Receive Oral Anticoagulation at Hospital Discharge
Black patients were also at significantly increased risk of stroke, bleeding, and mortality vs White patients 1 year following discharge.
Adult RSV Vaxx Gets EMA Nod: Can USA be Far Behind?
The GSK RSV vaccine candidate has received favorable international regulatory attention which may be an auspicious sign for the US.
Finerenone Mitigates HF, CV Risk Across Baseline Renal Function in Patients with T2D
The findings underscore the importance of routine eGFR and UACR screening in primary care to ensure early detection of CKD and avoid related adverse outcomes.